DRI Capital buys Ampyra royalty rights for $42 mln
Canadian private equity firm DRI Capital has purchased royalties relating to the worldwide sales of the drug Ampyra from Chicago-based healthcare institution Rush University Medical Center. The price for acquiring the royalties was approximately US$42 million. Ampyra is a therapy intended to help improve walking for people with multiple sclerosis. It was approved for use in the United States in January 2010 and has received conditional approval in Europe. The royalty rights were bought by Drug Royalty III, the third partnership of the Toronto-based DRI Capital, which closed last September at US$1.45 billion.
12 August 2014•5 mins read
